(ACER) – Press Releases
-
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
-
Moore Kuehn Encourages AGE, ACER, NXGN, and SUM Investors to Contact Law Firm
-
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
-
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
-
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
-
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
-
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
-
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
-
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
-
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial
-
Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update
-
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
-
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
-
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones
-
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
-
Acer Therapeutics Compliant with All Nasdaq Listing Criteria
-
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
-
Acer Therapeutics Announces $1.5M Private Placement
-
Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update
-
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)
-
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
-
Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency
-
Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder
-
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
-
Acer Therapeutics to Participate in August and September 2022 Investor Conferences
-
Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update
-
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
-
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
-
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
-
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
-
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
-
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
-
Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
-
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
-
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
-
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
-
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
-
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
-
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
-
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard
-
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
-
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021
-
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities
-
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
Back to ACER Stock Lookup
